Neurodegenerative diseases, which are progressive in nature and generally incurable, place a large and increasing burden on society and our healthcare systems. In recent years, novel gene variants have emerged which may hold the key to optimizing outcomes for these patients, as well as providing a path to a cure. G4C2 repeats in C9orf72, one of the most common genetic hallmarks in frontotemporal dementia (FTD) and amytotrophic lateral sclerosis (ALS, Lou Gehrig’s Disease), are such variants fueling research into how to better manage these devastating diseases. In this webinar, we will review how C9orf72 testing is moving from research to the clinic, the implications for patients and their families, and the exciting treatments on the horizon.

Back To
Top

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close